<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pediatr</journal-id><journal-title-group><journal-title>BMC Pediatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2431</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24620855</article-id><article-id pub-id-type="pmc">3975280</article-id><article-id pub-id-type="publisher-id">1471-2431-14-70</article-id><article-id pub-id-type="doi">10.1186/1471-2431-14-70</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Ballmann</surname><given-names>Manfred</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>M.Ballmann@klinikum-bochum.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Hubert</surname><given-names>Dominique</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>dominique.hubert@cch.aphp.fr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Assael</surname><given-names>Barouk M</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>baroukh.assael@ospedaleuniverona.it</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Kronfeld</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>kronfeld@izks-mainz.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Honer</surname><given-names>Marguerite</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>mhoner@muko.info</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Holl</surname><given-names>Reinhard W</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>reinhard.holl@uni-ulm.de</email></contrib><on-behalf-of>CFRD Study group<xref ref-type="corresp" rid="d33e66"/></on-behalf-of></contrib-group><aff id="I1"><label>1</label>Department Paediatric Pulmonology, Paediatric clinic at St Josef Hospital, Ruhr University Bochum, Alexandrinen Strasse 5, Bochum 44197, Germany</aff><aff id="I2"><label>2</label>Service de Pneumologie, APHP H&#x000f4;pital Cochin, Paris, France</aff><aff id="I3"><label>3</label>Ospedale Civile Maggiore, Verona, Italy</aff><aff id="I4"><label>4</label>Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre, Mainz, Germany</aff><aff id="I5"><label>5</label>Mukoviszidose Institut gGmbH, Bonn, Germany</aff><aff id="I6"><label>6</label>University of Ulm, Institute of Epidemiology and Medical Biometry, Ulm, Germany</aff><author-notes><corresp id="d33e66">CFRD Study group</corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>11</day><month>3</month><year>2014</year></pub-date><volume>14</volume><fpage>70</fpage><lpage>70</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Ballmann et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Ballmann et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2431/14/70"/><abstract><sec><title>Background</title><p>Diabetes mellitus may be present in patients with cystic fibrosis starting in the second decade of life. The prevalence increases rapidly with increasing age. As life-expectancy increases in cystic fibrosis, cystic fibrosis related diabetes will be diagnosed more frequently in the future.</p><p>Up to date, no data are available to answer the question if cystic fibrosis related diabetes should always initially be treated by insulin therapy. Missing data regarding oral antidiabetic treatment of newly diagnosed cystic fibrosis related diabetes are an important reason to recommend insulin treatment. Several centres report the successful management of cystic fibrosis related diabetes using oral anti-diabetic drugs at least for some years. Oral therapies would be less invasive for a patient group which is highly traumatized by a very demanding therapy. Based on an initiative of the German Mukoviszidosis-Foundation, the present study tries to answer the question, whether oral therapy with repaglinide is as effective as insulin therapy in cystic fibrosis patients with early diagnosed diabetes mellitus.</p></sec><sec><title>Methods/Design</title><p>In all cystic fibrosis patients with an age of 10&#x000a0;years or older, an oral glucose tolerance test is recommended. The result of this test is classified according to the WHO cut off values. It is required to have two diabetes positive oral glucose tolerance tests for the diagnosis of diabetes mellitus.</p><p>This study is a multi-national, multicentre, open labelled, randomized and prospective controlled parallel group&#x02019;s trial, with 24&#x000a0;months treatment.</p><p>The primary objective of this trial is to compare the glycaemic control of oral therapy with Repaglinide with insulin injections in patients with cystic fibrosis related diabetes after 2&#x000a0;years of treatment.</p><p>The trial should include 74 subjects showing cystic fibrosis related diabetes newly diagnosed by oral glucose tolerance test during annual screening for cystic fibrosis related diabetes.</p><p>Patients are randomised by central fax randomisation.</p><p>Primary endpoint is mean HbA1c after 24&#x000a0;months of treatment. Secondary endpoints are change in FEV1% predicted and change in BMI-Z-score.</p></sec><sec><title>Discussion</title><p>There is only one prospective study comparing oral antidiabetic drugs to insulin in the treatment of CFRD without fasting hyperglycaemia. The results regarding BMI after 6 months and 12 months showed an improvement for the insulin treated patients and were inconsistent for those treated with repaglinide. HbA1c and lung function (FEV1%pred) were unchanged for either group. The authors compared the changes -12 months to baseline and baseline to +12 months separately for each group. Therefore a direct comparison of the effect of repaglinide versus insulin on BMI, HbA1c and FEV1%pred was not presented. According to our protocol, we will directly compare treatment effects (HbA1c, BMI, FEV1%pred) in between both groups. The actual Cochrane report regarding &#x0201c;Insulin and oral agents for managing CFRD&#x0201d; stated that further studies are needed to establish whether there is clear benefit for hypoglycemic agents. We expect that the results of our study will help to address this clinical need.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00662714?term=repaglinide+and+insulin&#x00026;rank=9">NCT00662714</ext-link></p></sec></abstract><kwd-group><kwd>Cystic fibrosis</kwd><kwd>Diabetes mellitus</kwd><kwd>Lung diseases</kwd><kwd>Genetic diseases</kwd><kwd>Inborn</kwd><kwd>Repaglinide</kwd><kwd>Insulin</kwd><kwd>HbA1c</kwd><kwd>Clinical trial</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Diabetes mellitus may be present in patients with cystic fibrosis (CF) starting in the second decade of life. The prevalence increases rapidly with increasing age reaching around 30-40% in the fourth decade. As life-expectancy increases in CF, CF-related diabetes (CFRD) will be diagnosed more frequently in the future [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Negative consequences of CFRD include: catabolic metabolism, weight loss, more frequent/more severe infections, deterioration of pulmonary function, reduced life-expectancy and diabetic micro vascular complications [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Up to date, insulin is the only recommended treatment of CFRD, whether newly diagnosed or not. But no data are available to answer the question if CFRD must always initially be treated by insulin [<xref ref-type="bibr" rid="B3">3</xref>]. Several centres report the successful management of CF-related diabetes using oral anti-diabetic drugs at least for some years [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Oral therapies would be less invasive for a patient group which is highly traumatized by a very demanding pharmaceutical therapy (including antibiotics, pancreatic enzymes, bronchodilators, mucolytic agents) in addition to physiotherapy. Based on an initiative of the German CF-Foundation (Mukoviszidose e.V.), the present study tries to answer the question, whether oral therapy with repaglinide is as effective as insulin therapy in CF patients with early diagnosed diabetes mellitus.</p><sec><title>Primary objective</title><p>The primary objective of this trial is to compare the glycaemic control on oral therapy with repaglinide tid with that on insulin therapy with three daily injections of regular Insulin over 2&#x000a0;years in patients with CF and CFRD.</p></sec><sec><title>Secondary objectives</title><p>The secondary objectives of this trial are to compare the two treatment regimen (oral therapy with Repaglinide and insulin therapy with regular insulin) in terms of efficacy and safety.</p><p>The efficacy objectives are change in glycaemic control after 12&#x000a0;months of treatment, glycaemic control assessed by glucose profile done monthly (6 values), change in nutritional status and pulmonary function at 12 and 24&#x000a0;months, as well as the need for antibiotic treatments.</p><p>The safety objectives are the incidence and quality (mild, severe, other) of hypoglycaemic episodes and adverse events.</p></sec></sec><sec><title>Methods/Design</title><sec><title>Sponsor</title><p>The Mukoviszidose Institut gGmbH is the sponsor for this trial. Collaborators are Novo Nordisk, Mucoviscidose-ABCF2, Vaincre la Mucoviscidose and Assistance Publique - H&#x000f4;pitaux de Paris. The protocol and all trial documents have been approved by the ethic committees responsible for the respective trial sites. The first vote was received from the ethical committee of the MHH Hannover (22.08.2001, No. 2739). The responsible competent authorities gave approval (so far applicable) under EudraCT Number 2006-001254-27 [for France and Italy], BfArM Number 4019636 [for Germany] and BMSG Number 21.405/219 [for Austria]. The trial was public registered under ClinicalTrials.gov Identifier NCT00662714.</p></sec><sec><title>Eligibility criteria</title><p>Informed consent was to be obtained before any trial-related activities. CF was diagnosed by positive sweat test and/or two disease-causing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations. Patients had diagnosed diabetes mellitus by OGTT done less than six months before (one year before in Italy). The subjects were over 10&#x000a0;years of age (12&#x000a0;years in France and Italy). Diabetes was confirmed by a second OGTT test. Patients in France needed in addition fasting blood glucose levels &#x02264;170&#x000a0;mg/dl. Patients have been excluded with diagnosis of type 1 diabetes or diabetic keto-acidosis (blood glucose&#x02009;&#x0003e;&#x02009;350&#x000a0;mg/dl and arterial pH&#x02009;&#x0003c;&#x02009;7.25). Already treated diabetes mellitus by oral antidiabetic medication or insulin led to exclusion of these patients. Severe pulmonary insufficiency with FEV1&#x02009;&#x0003c;&#x02009;25% (France and Italy) or&#x02009;&#x0003c;&#x02009;40% (Germany and Austria), participation in another clinical trial less than one month before inclusion in this trial, severe liver insufficiency or PEG/gastric tube/total parenteral nutrition for more than 4&#x000a0;weeks were not at inclusion. Patients must not be pregnant and in France and Italy breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures were not allowed. Patients after transplantation or in France patients which have been planned for transplantation could not be included. For Germany subjects receiving concomitant medication known to interfere with repaglinide therapy were not included. In France and Italy proliferative retinopathy, type 2 diabetes, severe renal insufficiency, history of alcoholism, drug abuse, psychiatric disease or personality disorders likely to invalidate voluntary consent or to prevent good compliance with the trial protocol, legal incapacity or limited legal capacity, known or suspected allergy to the insulin or any compositional component, known or suspected allergy to repaglinide or receiving concomitant medication known to interfere with glucose metabolism prevented inclusion in this trial.</p></sec><sec><title>Trial conduct</title><p>In all CF-patients 10&#x000a0;years or older, an oral glucose tolerance test (OGTT) following standard WHO recommendations has be performed. Oral medication was postponed until after the test, however, inhalation therapy could be performed prior to the test. During acute infections or exacerbations of a chronic infection, the test was postponed for 3 to 4&#x000a0;weeks until acute symptoms improved. OGTT were classified as normal glucose tolerance, impaired glucose tolerance/impaired fasting glucose or diabetes mellitus according to the WHO cut off values [<xref ref-type="bibr" rid="B6">6</xref>].</p></sec><sec><title>Randomization</title><p>After detailed information by the physicians of the local CF centre, the patient or legal guardian decided to give written informed consent to participate in the study. The trial was open-labelled in order to avoid use of double-dummy technique which would have required an unacceptable increase in the number of injections for the patients. The patients were allocated to the treatment regimen according to a randomisation list generated by a geigy random number table by central fax randomisation. Stratification was conducted according to gender and two age groups (10&#x02013;15&#x000a0;years, &#x0003e;15&#x000a0;years). Every randomised patient should have been observed for at least 2&#x000a0;years and be included in the final analysis (&#x0201c;intention-to-treat&#x0201d; analysis).</p><p>The trial procedures are summarised in the following Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Trial procedures</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left" valign="top"><bold>Visits/months</bold></th><th rowspan="2" align="center" valign="top"><bold>VS</bold></th><th align="center" valign="bottom"><bold>V1</bold><hr/></th><th align="center" valign="bottom"><bold>V2</bold><hr/></th><th align="center" valign="bottom"><bold>V3</bold><hr/></th><th align="center" valign="bottom"><bold>V4</bold><hr/></th><th align="center" valign="bottom"><bold>V5</bold><hr/></th><th align="center" valign="bottom"><bold>V6</bold><hr/></th><th align="center" valign="bottom"><bold>V7</bold><hr/></th><th align="center" valign="bottom"><bold>V8</bold><hr/></th><th align="center" valign="bottom"><bold>V9</bold><hr/></th><th rowspan="2" align="center" valign="top"><bold>End</bold></th></tr><tr><th align="center"><bold>0</bold></th><th align="center"><bold>3</bold></th><th align="center"><bold>6</bold></th><th align="center"><bold>9</bold></th><th align="center"><bold>12</bold></th><th align="center"><bold>15</bold></th><th align="center"><bold>18</bold></th><th align="center"><bold>21</bold></th><th align="center"><bold>24</bold></th></tr></thead><tbody><tr><td align="center" valign="bottom">Informed consent<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Selection/exclusion criteria<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Randomisation<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Inclusion/exclusion criteria<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Demographic data<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Medical history<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="center" valign="bottom">Physical examination<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">Concomitant illness and medication<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">Blood glucose profile<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">HbA<sub>1c</sub><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">Pulmonary function<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">IV therapy (antibiotics)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">Adverse events<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center" valign="bottom">Hypoglycaemic episodes<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td><td align="center" valign="bottom">+<hr/></td></tr><tr><td align="center">Drug dispensation</td><td align="center">&#x000a0;</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">+</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec><title>Interventions</title><sec><title>Therapeutic regimen repaglinide</title><p>Therapy started with 3 &#x000d7; 0.5&#x000a0;mg Repaglinide before the main meals. If one meal has been skipped or consisted only of carbohydrate-free food, tablet intake was not recommended. Therapy adjustment (dose increase to 3 &#x000d7; 1 mg or dose reduction to 3 &#x000d7; 0.25&#x000a0;mg) occurred basing on blood glucose level measured 2&#x000a0;hours after a meal. The target value should have been 70&#x02013;160&#x000a0;mg/dl. If the majority of values were above 160&#x000a0;mg/dl, the dose should have been further increased but not earlier than one week after start of therapy. The maximum dose in this study should have been 12&#x000a0;mg (3 &#x000d7; 4&#x000a0;mg). If low blood glucose levels (hypoglycaemia symptoms or blood glucose level below 50&#x000a0;mg/dl) occurred postprandial or before the next main meal, the repaglinide dose should have been reduced (see Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Asymptomatic blood glucose levels between 50 and 60&#x000a0;mg/dl could have been tolerated. For some patients, different doses before breakfast, lunch and dinner could have been reasonable.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Algorithm for dose adjustment of repaglinide.</p></caption><graphic xlink:href="1471-2431-14-70-1"/></fig><p>During the adjustment phase up to 6 measurements of blood glucose levels were recommended (pre-and postprandial after the main meals respectively). After a stable adjustment was achieved, this number might be reduced for every patient individually, but one postprandial measuring of blood glucose levels had to be maintained daily. Each postprandial blood glucose level had to be checked at least once a week.</p><p>Reasons for choosing repaglinide as oral anti-diabetic.</p><p>A decreased insulin secretion appeared to be part of CF-diabetes pathogenesis repeatedly. Biguanides, sensitizers and glycosidase inhibitors are only of restricted use with CF patients due to the chemicals&#x02019; hepatic or gastrointestinal side effects. In Germany, the most extensive experience with oral anti-diabetics in CF-associated diabetes mellitus therapy has been with glibenclamide [<xref ref-type="bibr" rid="B7">7</xref>]. Because of its longer lasting effect the risk of hypoglycaemia, especially when meals are skipped, is higher compared to repaglinide. The latter can be adapted to meals more conveniently. For these reasons glimepiride was not chosen for this study. Nateglinide is a substance whose effects profile is similar to that of repaglinide. This substance was still under approval at the date designing this trial while therapy using repaglinide had already been documented extensively. Therefore, nateglinide was not chosen.</p><p>There are individual reports of successful use of repaglinide during CF diabetes [<xref ref-type="bibr" rid="B8">8</xref>]; this substance is also used in the USA in a study of adult CF patients with diabetes mellitus (Principal investigator: A. Moran, MD, Minneapolis) [<xref ref-type="bibr" rid="B9">9</xref>].</p></sec></sec><sec><title>Therapeutic regimen insulin</title><p>Insulin therapy should have been conducted by three injections of Regular Insulin, each time immediately before the main meals. With asymptomatic patients, therapy should begin with 0.05 units per kg weight and injection. The dose was adjusted with regard to postprandial (2&#x000a0;hours after meal) glucose levels: The dose should be adjusted by about 10&#x02013;20%, approximated to full or half units (see Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>). Patients injected insulin using insulin pens.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Algorithm for insulin adjustment.</p></caption><graphic xlink:href="1471-2431-14-70-2"/></fig><p>During the adjustment phase, up to 6 blood glucose measurements were recommended (each pre- and postprandial). After a stable metabolism adjustment was attained, this number could have been reduced individually; however, every postprandial level had to be checked once a week. 3 daily measurements were the minimum, especially when using higher insulin doses (&#x0003e;0.3 units/kg and day). Patients with varying blood glucose levels should have been educated about blood glucose corrections based on body weight and insulin demand. If the absorbable carbohydrate content of meals changed significantly on a daily basis, then a separate carbohydrate exchange unit factor for every meal based on pre- and postprandial measurements had to be determined.</p></sec><sec><title>Reason for the choice of insulin therapy scheme</title><p>For insulin therapy of CF patients, conventional schemes (1&#x02013;2 injections a day, fixed or varying mixtures of regular- and NPH-insulin) are advocated as well as intensified therapy schemes with 3, 4 or more injections and flexible adaptation of insulin doses to the expected food intake and the measured blood glucose level [<xref ref-type="bibr" rid="B9">9</xref>]. The study described here aimed at CF patients who have been diagnosed early, thus making an intensified therapy scheme unnecessary. In the case of type 2-therapy, which shows some parallels to CFRD, recent years have shown a development away from doses of premixed insulin with high NPH contents and towards pre-prandial doses of regular insulin [<xref ref-type="bibr" rid="B10">10</xref>]. Most CF diabetes patients show very high postprandial blood glucose levels, whereas fasting values and pre-prandial values remained normal for a long time. Therefore, a therapy of 3 regular insulin injections is advisable from a pathophysiological viewpoint. A dose of 3 injections a day for CF patients with an early diagnosis of diabetes mellitus appeared to be a viable compromise between the two aims &#x02013; to apply a therapy scheme as simple as possible and to optimise a patient&#x02019;s blood glucose levels at the same time.</p></sec><sec><title>Diabetes education at the onset of therapy</title><p>All CF patients with newly diagnosed diabetes mellitus had to be educated intensively about food formulations, effects of food on blood glucose, blood glucose measuring, blood glucose documentation, risk of hypoglycaemia during therapy, treatment of hypoglycaemia, long-term effects of high blood glucose levels, and characteristics of diabetes mellitus with CF. Patients who have been randomised to insulin therapy had to be taught additionally about injecting, storage of insulin and dose adjustment.</p></sec><sec><title>Therapy duration</title><p>Patients in both therapy strains hade to be monitored for 2&#x000a0;years; every 3&#x000a0;months, a standardised examination and documentation was intended.</p></sec><sec><title>Reasons for study duration</title><p>No relevant short-term changes have been expected among early diagnosed patients, especially concerning weight development and lung function [<xref ref-type="bibr" rid="B11">11</xref>]. Evidence of successful diabetes therapy with an oral anti-diabetic stretching over 2&#x000a0;years was planned to show constitute clinically relevant results compared with a shorter duration.</p></sec><sec><title>Discontinuation criteria</title><p>The therapy in one of the therapy strains should have been considered ineffective if one of the following discontinuation criteria had been met: No acceptable metabolic control obtainable over a time span of 3&#x000a0;months regardless of dose adjustment according to protocol and therapy compliance; occurrence of non-tolerable undesired side effects under therapy; transaminase increase to 3 times the initial value; non tolerable allergic reactions; discontinuation of study by patient/family; se of systemic steroids necessary; desired or occurring pregnancy; PEG/nasal tube feeding/completely parental alimentation of at least 4 successive weeks or transplantation.</p></sec><sec><title>Therapy alternatives when reaching discontinuation criterion</title><p>a. Insufficient metabolism control during therapy with repaglinide.</p><p>Generally, a shift to insulin would have been necessary; doses of 3 injections of regular insulin before meals were recommended. If fasting blood glucose levels had been high, an additional dose of intermediate/long-lasting insulin before going to sleep was advisable. A shift from repaglinide to glibenclamide would have make sense only if allergic reactions to repaglinide occurred. The use of other oral anti-diabetics could not be recommended based on current scientific knowledge.</p><p>b. Insufficient metabolic/glycaemic control during therapy with three injections of regular insulin.</p><p>Usually a standard intensified therapy of 4&#x02013;5 injections a day was recommended.</p></sec><sec><title>Outcome measures</title><p>Primary endpoint:</p><p>Primary endpoint was the change in HbA1c after 24&#x000a0;months of treatment.</p><p>Secondary endpoints:</p><p>Secondary endpoints were glycaemic control assessed by mean HbA1C and mean blood glucose profile; change in BMI-Z-score; change in FEV1% predicted and safety assessed by antibiotic therapy, incidence of adverse events, number of hypoglycaemic episodes, all symptomatic hypoglycaemia, hypoglycaemia that necessitates the help of other persons, hypoglycaemia with unconsciousness or coma and number of blood glucose levels below 50&#x000a0;mg/dl in relation to all blood glucose measurements.</p></sec><sec><title>Quality assurance</title><p>Clinical on-site monitoring in all trial centres was done by personal visits of a clinical monitor according to standard operating procedures of the Interdisciplinary Centre for Clinical Trials (IZKS) Mainz starting 2008. The monitor checked the informed consent forms and reviewed the entries into the case report form (CRF) on the basis of source documents. The physician allowed the monitor access to at all essential documents and provides support to the monitor. The IZKS Mainz assisted the physician to conduct the study according to the protocol as well as to regulatory and ethical requirements.</p></sec><sec><title>Data management</title><p>University of Ulm conducted the data management of the trial. All protocol-required information collected during the study had been entered by the investigator, or a designated representative in the CRF. CRF data were entered by University of Ulm into the database. During the study, data were exported into the statistical analysis system and checked additionally for plausibility, consistency and completeness. Based on these checks, queries have been produced. Any missing data or inconsistencies were reported back to the respective site and clarified by the responsible investigator. After all corrections were done, the database was closed and used for statistical analysis. All collected data have been processed according to the German Data Protection Law and handled in strictest confidence.</p></sec><sec><title>Power calculation/analysis</title><p>Which number of patients was necessary to show a significant difference between therapy strains of 80% power on the one hand and p &#x0003c;0.05 on the other? Retrospective HbA1c data from a database of the CF centre at Medical School Hannover were used. Measurements of n&#x02009;=&#x02009;132 HbA1c within the first two years after diabetes diagnosis of n&#x02009;=&#x02009;44 patients older than 10&#x000a0;years at the date of diagnosis resulted in an average value of HbA1c&#x02009;=&#x02009;5.6&#x02009;&#x000b1;&#x02009;1.5 (average value&#x02009;&#x000b1;&#x02009;SD). Within a similar group (older than 10&#x000a0;years) but without diabetes n&#x02009;=&#x02009;763 measurements yielded an HbA1c of 4.6&#x02009;&#x000b1;&#x02009;0.68 (average value&#x02009;&#x000b1;&#x02009;SD). A difference of 1 (which is in the range of individual variations during treatment especially in youngsters and young adults) between therapy groups was considered relevant [<xref ref-type="bibr" rid="B12">12</xref>]. Calculation with <italic>n Query&#x000ae;</italic> of necessary patients for each group was done with these parameters: Two group <italic>t</italic>-test of equal means (equal n&#x02019;s) 1; Test significance level, &#x003b1; 0,050; 2 sided test; Group 1 mean, &#x003bc;<sub>1</sub> 5,600; Group 2 mean, &#x003bc;<sub>2</sub> 4,760; Difference in means, &#x003bc;<sub>1</sub> - &#x003bc;<sub>2</sub> 1,000; Common standard deviation, &#x003c3; 1,500; Effect size, &#x003b4; = |&#x003bc;<sub>1</sub> - &#x003bc;<sub>2</sub>|/&#x003c3; 0,667; Power 80%. Based on the above assumptions the number of patients in each group was calculated as n&#x02009;=&#x02009;37. Over a treatment time of 2&#x000a0;years, about 30% of patients were assumed to drop out of the study. Therefore, n&#x02009;=&#x02009;111 patients have been necessary at the beginning of the study to ensure a number of n&#x02009;=&#x02009;74 remaining patients at the end of the study.</p><p>For analysis, the differences of primary parameter HbA1c repeated measures-ANOVA will be applied. The one-sided zero hypothesis (Repaglinide is not worse than insulin) will be dismissed if a p value under 0.05 occurs. The two therapy groups will be compared concerning secondary parameters statistically using the fisher exact test (comparison of discrete events), the Wilcoxon (non-parametrically distributed parameters) and the <italic>t</italic>-test (parametrically distributed parameters). For comparison of drop-outs between the treatment stains a Cox proportional-hazard-ratio model will be applied.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>As many other treatments the use of oral antidiabetic drugs in patients with CFRD isn&#x02019;t officially approved. Guidelines recommend insulin as first line treatment [<xref ref-type="bibr" rid="B2">2</xref>]. Nevertheless there are many centers which use oral antidiabetic drugs for treatment of CFRD [<xref ref-type="bibr" rid="B3">3</xref>]. The reasons for this off label use might be the hope to reduce the treatment burden which is even without CFRD very high in CF [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. The only published prospective study comparing oral antidiabetic drugs to insulin in the treatment of CFRD without fasting hyperglycaemia [<xref ref-type="bibr" rid="B9">9</xref>] followed patients for 12 months only. The results regarding BMI after 6 months and 12 months were inconsistent for those treated with repaglinide and showed an improvement for the insulin treated patients. There was no change in HbA1c or lung function (FEV1%pred) for either group (insulin, repaglinide and placebo). An important difference to the present study protocol was the way how effects of repaglinide and insulin were evaluated. According to our protocol, we will directly compare treatment effects (HbA1c, BMI, FEV1%pred) in between both groups. In the recent published study the authors compared the changes -12 months to baseline and baseline to +12 months [<xref ref-type="bibr" rid="B9">9</xref>] separately for each group. Therefore a direct comparison of the effect of repaglinide versus insulin on BMI, HbA1c and FEV1%pred was not presented. The actual Cochrane report [<xref ref-type="bibr" rid="B3">3</xref>] regarding &#x0201c;Insulin and oral agents for managing cystic fibrosis-related diabetes&#x0201d; stated that further studies are needed to establish whether there is clear benefit for hypoglycemic agents. We expect that the results of our study will help to address this clinical need.</p><sec><title>Trial status</title><p>1093 CF patients with no previous diagnosis of CFRD and age of 10&#x000a0;years or older were screened for eligibility by at least two valid OGTTs each. For 145 patients CFRD could be diagnosed [<xref ref-type="bibr" rid="B14">14</xref>]. The first patient was included on 13.03.2002 and the last patient on 01.12.2009. The analysis of trial data is ongoing.</p></sec></sec><sec><title>Abbreviations</title><p>ANOVA: Analysis of variance; BfArM: Bundesinstitut f&#x000fc;r Arzneimittel und Medizinprodukte; BMI: Body mass index; BMSG: Bundesministerium f&#x000fc;r soziale Sicherheit und Generationen; CF: Cystic fibrosis; CFRD: Cystic fibrosis related diabetes; CFTR: Cystic fibrosis transmembrane conductance regulator; CRF: Case report form; CYP: Cytochrome P450; EudraCT: European clinical trials database; FEV1: Forced expiratory volume in 1&#x000a0;second; HbA1c: Glycosylated haemoglobin; IZKS: Interdisciplinary centre for clinical trials; NCT: National clinical trial number; OGTT: Oral glucose tolerance test; NPH: Neutral protamine Hagedorn; PEG: Percutaneous endoscopic gastrostomy; SD: Standard deviation; V: Visit; WHO: World Health Organisation.</p></sec><sec><title>Competing interests</title><p>The study was funded by the Mukoviszidose e.V. (German CF-Foundation), Vaincre la Mucoviscidose (French CF-Foundation) and ABCF Association (France). CF Foundation (Mukoviszidose e.V.). The medication was a gift from Novo Nordisk, Germany.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MB and RH designed the trial. All authors made a substantial contribution to the trial protocol. All authors read, commentated and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2431/14/70/prepub">http://www.biomedcentral.com/1471-2431/14/70/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>CFRD-Study Group</p><p>Germany</p><p>1. U. Staden, Berlin, Zentralklinik Emil-von-Behring/Dept. Lungenklinik</p><p>2. M. Cla&#x000df;en, Bremen, Zentralkrankenhaus &#x0201c;Links der Weser&#x0201d;/Klinik f&#x000fc;r Kinder- und Jugendmedizin</p><p>3. A. Schuster, D&#x000fc;sseldorf, Universit&#x000e4;tskinderklinik/Ambulanz II</p><p>4. U. Mellies, Essen, Universit&#x000e4;tsklinikum GHS Essen/Klinik f&#x000fc;r Kinder und Jugendliche</p><p>5. HG. Posselt, Frankfurt/Main, Zentrum der Kinderheilkunde/Abt. Allgemeine P&#x000e4;diatrie I</p><p>6. M. Ballmann, Hannover, MHH/Abt. Kinderheilkunde 1/CF-Ambulanz</p><p>7. M. Wiebel, Heidelberg, Thoraxklinik gGmbH/Innere Medizin Pneumologie</p><p>8. E. Rietschel, K&#x000f6;ln, Klinikum der Univ. zu K&#x000f6;ln/Zentrum f. Kinder- und Jugendmedizin/P&#x000e4;d. Pneumologie</p><p>9. M. Stern, T&#x000fc;bingen, Universit&#x000e4;tsklinik T&#x000fc;bingen/Poliklinik</p><p>10. H. Teschler, Essen, Ruhrlandklinik Essen/CF-Ambulanz f. Erwachsene</p><p>11. C. Smaczny, Frankfurt/Main, Med. Klinik II/Allergologie und Pneumologie</p><p>12. T. K&#x000f6;hnlein, Hannover, MHH/Pneum. Ambulanz I/OE 6870/CF-Ambulanz f. Erwachsene</p><p>13. V. Wienhausen-Wilke, Gerlingen, Klinik Schillerh&#x000f6;he/Zentrum f&#x000fc;r Pneumologie und Thoraxchirurgie/CF-Ambulanz</p><p>14. A. Claa&#x000df;, Kiel, St&#x000e4;dt. Krankenhaus/Klinik f. Kinder- und Jugendmedizin</p><p>15. T. Biedermann, Berlin, Helios-Klinikum Berlin-Buch/Klinik f&#x000fc;r Kinder- und Jugendmedizin/CF- Ambulanz</p><p>16. L. N&#x000e4;hrlich, Erlangen, Klinik mit Poliklinik f&#x000fc;r Klinder und Jugendliche/Sozialp&#x000e4;diatrisches Zentrum/CF-Ambulanz</p><p>17. G. Dockter, Homburg/Saar, Universit&#x000e4;tsklinik f&#x000fc;r Kinder- und Jugendmedizin</p><p>18. H. K&#x000f6;ster, Oldenburg, Kinderklinik Oldenburg</p><p>19. A. Hebestreit, W&#x000fc;rzburg, Julius-Maximilians-Universit&#x000e4;t/Kinderpoliklinik</p><p>20. EH. Balke, Greifswald, Klinik und Poliklinik f&#x000fc;r Kinder- und Jugendmedizin der Universit&#x000e4;t Greifswald/CF-Ambulanz</p><p>21. HE. Heuer, Hamburg, Altona-Klinik/CF-Ambulanz</p><p>22. W. Kamin, Mainz, Universit&#x000e4;tsklinik/P&#x000e4;d. Pneumologie</p><p>23. P. K&#x000fc;ster, M&#x000fc;nster, Klinik f&#x000fc;r Kinder- und Jugendmedizin Clemenshospital</p><p>24. R. Szczepanski, Osnabr&#x000fc;ck Kinderhospital Osnabr&#x000fc;ck</p><p>25. KM. Keller, Wiesbaden, DKD Wiesbaden/Kinderheilkunde</p><p>26. H. Generlich, Berlin, Klinik f&#x000fc;r Kinder-und Jugendmedizin/CF-Ambulanz</p><p>27. HG Bresser, Bielefeld, Kinderzentrum der Krankenanstalten Gilead/P&#x000e4;d. Pneumologie</p><p>28. M. Kopp, Freiburg, Universit&#x000e4;tsklinikum Freiburg/Kinderklinik</p><p>29. E. Herting, G&#x000f6;ttingen, Georg-August-Universit&#x000e4;t G&#x000f6;ttingen/Kinderklinik und Poliklinik 7 CF-Ambulanz</p><p>30. K. Kreger, Halle, Martin-Luther-Universit&#x000e4;t Wittenberg/Klinikum Kr&#x000f6;llwitzt/Kinderklinik/CF-Ambulanz</p><p>31. HJ. Feikert, Neubrandenburg, Klinikum Neubrandenburg/Kinderklinik</p><p>32. J. Hautz, Offenburg, Kinderklinik Offenburg</p><p>33. B. Schilling, Passau, Kinderklinik Dritter Orden/Sozialp&#x000e4;diatrisches Zentrum</p><p>34. E. Meyer, Wilhelmshaven, Kinderklinik des Reinhard-Nieter-Krankenhauses</p><p>35. M. Mall, Heidelberg, Klinikum der Universit&#x000e4;t Heidelberg/Kinderklinik Abt. III/CF-Ambulanz</p><p>36. W. Wiebicke, Bremen, Prof. Hess-Kinderklinik/Zentralkrankenhaus</p><p>37. FK, Tegtmeyer, Kassel, Kinderkrankenhaus Park Sch&#x000f6;nfeld</p><p>Italy</p><p>1. B. Assael, Verona, Centro Regionale Veneto per la Fibrosi Cistica, Azienda Ospedaliera Universitaria Integrata di Verona</p><p>France</p><p>1. D. Hubert, Paris, cystic fibrosis centre and service de pneumologie, h&#x000f4;pital Cochin APHP</p><p>2. H. Mosnier-Pudar, Paris, service d&#x02019;endocrinologie, h&#x000f4;pital Cochin APHP</p><p>3. G. Lenoir, Paris, cystic fibrosis centre and service de p&#x000e9;diatrie, h&#x000f4;pital Necker</p><p>4. Jean-Jacques Robert, Paris, cystic fibrosis centre and service d&#x02019;endocrinologie, h&#x000f4;pital Necker -</p><p>5. L. Kessler, Strasbourg, Service d&#x02019;endocrinologie, Universit&#x000e9; de Strasbourg</p><p>6. L. Weiss, Strasbourg, cystic fibrosis centre and service de p&#x000e9;diatrie, H&#x000f4;pital de Hautepierre</p><p>7. R. Nove-Josserand, Lyon, Cystic fibrosis centre and Service de M&#x000e9;decine Interne, H&#x000f4;pital Lyon Sud</p><p>8. MC. Vantygehm, Lille, Service d&#x02019;Endocrinologie, Centre Hospitalier et Universitaire de Lille</p><p>9. A. Munck, Paris, Cystic fibrosis centre and Service de P&#x000e9;diatrie &#x02013; H&#x000f4;pital Robert Debr&#x000e9; APHP</p><p>10. N Wizla, Lille, cystic fibrosis centre and service de P&#x000e9;diatrie</p><p>11. S. Leroy, Lille, cystic fibrosis centre and service de Pneulologie</p><p>12. GA. Loeuille, Dunkerque, Service de P&#x000e9;diatrie&#x02013; Centre Hospitalier de Dunkerque</p><p>Austria</p><p>1. D. Thalhammer, Graz, Univ. Klinik f. Kinder- und Jugendheilkunde</p><p>2. I. Huttegger, Salzburg, St. Johanns Spital - Landeskrankenhaus, Abt. Kinder- u. Jugendheilkunde</p><p>3. I. Eichler, Wien, Univ. Klin. f. Kinder- u. Jugendheilkunde</p><p>4. M. G&#x000f6;tz, Wien, Wilhelminenspital der Stadt Wien</p><p>For Financial support: Mukoviszidose e.V. (German CF-Foundation), Vaincre la Mucoviscidose (French CF-Foundation) and ABCF Association (France), NovoNordisk Germany</p><p>For local study organisation: Mukoviszidose Institut (A. Reimann), Germany and URC Cochin-Necker (R. Serreau and F. Aissat), France</p><p>For performing central HbA1c measurements: Prof. Dr. Elisabeth Kohne (Department of Paediatrics and Adolescent Medicine, University Hospital Ulm).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>A</given-names></name><article-title>Update on cystic fibrosis-related diabetes</article-title><source>J Cyst Fibros</source><year>2013</year><volume>12</volume><issue>4</issue><fpage>318</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2013.02.008</pub-id><pub-id pub-id-type="pmid">23562217</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Brunzell</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>RC</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>BC</given-names></name><name><surname>Onady</surname><given-names>G</given-names></name><name><surname>Robinson</surname><given-names>KA</given-names></name><name><surname>Sabadosa</surname><given-names>KA</given-names></name><name><surname>Stecenko</surname><given-names>A</given-names></name><name><surname>Slovis</surname><given-names>B</given-names></name><article-title>Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>12</issue><fpage>2697</fpage><lpage>2708</lpage><pub-id pub-id-type="doi">10.2337/dc10-1768</pub-id><pub-id pub-id-type="pmid">21115772</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Onady</surname><given-names>GM</given-names></name><name><surname>Stolfi</surname><given-names>A</given-names></name><article-title>Insulin and oral agents for managing cystic fibrosis-related diabetes</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>7</volume><comment>CD004730</comment></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Fischman</surname><given-names>D</given-names></name><name><surname>Nookala</surname><given-names>VK</given-names></name><article-title>Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management</article-title><source>Endocr Pract</source><year>2008</year><volume>14</volume><issue>9</issue><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.4158/EP.14.9.1169</pub-id><pub-id pub-id-type="pmid">19158056</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Onady</surname><given-names>GM</given-names></name><name><surname>Stolfi</surname><given-names>A</given-names></name><article-title>Insulin and oral agents for managing cystic fibrosis-related diabetes</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><volume>3</volume><comment>CD004730</comment></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Mueller-Brandes</surname><given-names>C</given-names></name><name><surname>Holl</surname><given-names>RW</given-names></name><name><surname>Nastoll</surname><given-names>M</given-names></name><name><surname>Ballmann</surname><given-names>M</given-names></name><article-title>New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis</article-title><source>Eur Respir J</source><year>2005</year><volume>25</volume><issue>4</issue><fpage>715</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1183/09031936.05.00068104</pub-id><pub-id pub-id-type="pmid">15802348</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Rosenecker</surname><given-names>J</given-names></name><name><surname>Eichler</surname><given-names>I</given-names></name><name><surname>Barmeier</surname><given-names>H</given-names></name><name><surname>von der Hardt</surname><given-names>H</given-names></name><article-title>Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents</article-title><source>Pediatr Pulmonol</source><year>2001</year><volume>32</volume><issue>5</issue><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1002/ppul.1143</pub-id><pub-id pub-id-type="pmid">11596159</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Onady</surname><given-names>GM</given-names></name><name><surname>Langdon</surname><given-names>LJ</given-names></name><article-title>Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study</article-title><source>BMC Endocr Disord</source><year>2006</year><volume>6</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1472-6823-6-4</pub-id><pub-id pub-id-type="pmid">16790062</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Moran</surname><given-names>A</given-names></name><name><surname>Pekow</surname><given-names>P</given-names></name><name><surname>Grover</surname><given-names>P</given-names></name><name><surname>Zorn</surname><given-names>M</given-names></name><name><surname>Slovis</surname><given-names>B</given-names></name><name><surname>Pilewski</surname><given-names>J</given-names></name><name><surname>Tullis</surname><given-names>E</given-names></name><name><surname>Liou</surname><given-names>TG</given-names></name><name><surname>Allen</surname><given-names>H</given-names></name><article-title>Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>10</issue><fpage>1783</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.2337/dc09-0585</pub-id><pub-id pub-id-type="pmid">19592632</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="book"><name><surname>Bretzel</surname><given-names>RG</given-names></name><person-group person-group-type="editor">Haering HU, Gallwitz B, Mueller-Wieland D, Usadel K-H, Mehnert H</person-group><article-title>Diagnostik und Therapie</article-title><source>Diabetologie in Klinik und Praxis</source><year>2011</year><edition>6</edition><publisher-name>Stuttgart, New York: Thieme</publisher-name><fpage>192</fpage><lpage>211</lpage></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Lanng</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>A</given-names></name><name><surname>Thorsteinsson</surname><given-names>B</given-names></name><name><surname>Nerup</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><article-title>Glucose tolerance in patients with cystic fibrosis: five year prospective study</article-title><source>Bmj</source><year>1995</year><volume>311</volume><issue>7006</issue><fpage>655</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1136/bmj.311.7006.655</pub-id><pub-id pub-id-type="pmid">7549632</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Ziaian</surname><given-names>T</given-names></name><name><surname>Sawyer</surname><given-names>MG</given-names></name><name><surname>Reynolds</surname><given-names>KE</given-names></name><name><surname>Carbone</surname><given-names>JA</given-names></name><name><surname>Clark</surname><given-names>JJ</given-names></name><name><surname>Baghurst</surname><given-names>PA</given-names></name><name><surname>Couper</surname><given-names>JJ</given-names></name><name><surname>Kennedy</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>AJ</given-names></name><name><surname>Staugas</surname><given-names>RE</given-names></name><name><surname>French</surname><given-names>DJ</given-names></name><article-title>Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma</article-title><source>J Paediatr Child Health</source><year>2006</year><volume>42</volume><issue>10</issue><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1754.2006.00943.x</pub-id><pub-id pub-id-type="pmid">16972965</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Sawicki</surname><given-names>GS</given-names></name><name><surname>Sellers</surname><given-names>DE</given-names></name><name><surname>Robinson</surname><given-names>WM</given-names></name><article-title>High treatment burden in adults with cystic fibrosis: challenges to disease self-management</article-title><source>J Cyst Fibros</source><year>2009</year><volume>8</volume><issue>2</issue><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2008.09.007</pub-id><pub-id pub-id-type="pmid">18952504</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Schmid</surname><given-names>K</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Holl</surname><given-names>RW</given-names></name><name><surname>Hebestreit</surname><given-names>H</given-names></name><name><surname>Ballmann</surname><given-names>M</given-names></name><article-title>Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test</article-title><source>J Cyst Fibros</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2013.06.001</pub-id><pub-id pub-id-type="pmid">23809507</pub-id></mixed-citation></ref></ref-list></back></article>